My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 224

    1.

    A model educational program for people with type 2 diabetes: a cooperative Latin American implementation study (PEDNID-LA).

    Gagliardino JJ, Etchegoyen G; PENDID-LA Research Group.

    Diabetes Care. 2001 Jun;24(6):1001-7.PMID: 11375360 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55).

    Davis TM, Cull CA, Holman RR; U.K. Prospective Diabetes Study (UKPDS) Group.

    Diabetes Care. 2001 Jul;24(7):1167-74.PMID: 11423497 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: the Fremantle Diabetes Study.

    Clifford RM, Davis WA, Batty KT, Davis TM; Fremantle Diabetes Study.

    Diabetes Care. 2005 Apr;28(4):771-6.PMID: 15793171 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

    Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

    5.

    Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Fassi R, Fogari R.

    Clin Ther. 2007 Apr;29(4):602-10.PMID: 17617283 [PubMed - indexed for MEDLINE]Related articles

    6.

    A pharmacotherapy follow-up program in patients with type-2 diabetes in community pharmacies in Spain.

    Fornos JA, Andrés NF, Andrés JC, Guerra MM, Egea B.

    Pharm World Sci. 2006 Apr;28(2):65-72. Epub 2006 Jun 22.PMID: 16791717 [PubMed - indexed for MEDLINE]Related articles

    7.

    Group visits improve metabolic control in type 2 diabetes: a 2-year follow-up.

    Trento M, Passera P, Tomalino M, Bajardi M, Pomero F, Allione A, Vaccari P, Molinatti GM, Porta M.

    Diabetes Care. 2001 Jun;24(6):995-1000.PMID: 11375359 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial.

    Ménard J, Payette H, Baillargeon JP, Maheux P, Lepage S, Tessier D, Ardilouze JL.

    CMAJ. 2005 Dec 6;173(12):1457-66. Epub 2005 Nov 17.PMID: 16293781 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    The relationship between self-monitoring of blood glucose control and glycosylated haemoglobin in patients with type 2 diabetes with and without diabetic retinopathy.

    Ozmen B, Boyvada S.

    J Diabetes Complications. 2003 May-Jun;17(3):128-34.PMID: 12738396 [PubMed - indexed for MEDLINE]Related articles

    10.

    Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

    Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

    Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

    11.

    Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.

    Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, Knight D, Grossman L, Oakley D, Tan M; H6E-MC-GLAT study group.

    Clin Ther. 2005 May;27(5):554-67.PMID: 15978304 [PubMed - indexed for MEDLINE]Related articles

    12.

    [Structured treatment and teaching programs and an improvement in private health care lead to a better quality of diabetes care. JEVIN, a population-based trial 1989/90 up to 1999/2000]

    Schiel R, Müller UA.

    Med Klin (Munich). 2003 Jun 15;98(6):303-12. German. PMID: 12811414 [PubMed - indexed for MEDLINE]Related articles

    13.

    Improvement of glycaemic control in type 2 diabetes: favourable changes in blood pressure, total cholesterol and triglycerides, but not in HDL cholesterol, fibrinogen, Von Willebrand factor and (pro)insulin.

    Becker A, van der Does FE, van Hinsbergh VW, Heine RJ, Bouter LM, Stehouwer CD.

    Neth J Med. 2003 Apr;61(4):129-36.PMID: 12852722 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    ["Diabetes in Germany"(DIG) study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practice]

    Ott P, Benke I, Stelzer J, Köhler C, Hanefeld M.

    Dtsch Med Wochenschr. 2009 Feb;134(7):291-7. Epub 2009 Feb 5. German. PMID: 19197810 [PubMed - indexed for MEDLINE]Related articles

    15.

    Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

    Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

    16.

    A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.

    Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR.

    Clin Ther. 2007 Sep;29(9):1900-14.PMID: 18035190 [PubMed - indexed for MEDLINE]Related articles

    17.

    Effectiveness of comprehensive diabetes care program in Taiwanese with type 2 diabetes.

    Tien KJ, Hung HC, Hsiao JY, Hsu SC, Hsin SC, Shin SJ, Hsieh MC.

    Diabetes Res Clin Pract. 2008 Feb;79(2):276-83. Epub 2007 Sep 27.PMID: 17904243 [PubMed - indexed for MEDLINE]Related articles

    18.

    The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.

    Rajagopalan R, Xu Y, Abbadessa M; Quartet Study Group.

    Am J Geriatr Pharmacother. 2006 Jun;4(2):123-33.PMID: 16860259 [PubMed - indexed for MEDLINE]Related articles

    19.

    Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

    Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

    Clin Ther. 2005 Sep;27(9):1383-91.PMID: 16291411 [PubMed - indexed for MEDLINE]Related articles

    20.

    Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study.

    Martin S, Kolb H, Beuth J, van Leendert R, Schneider B, Scherbaum WA.

    Diabetologia. 2003 Dec;46(12):1611-7. Epub 2003 Nov 5.PMID: 14600814 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity